Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Trethera logo — company profile

Trethera

Founded 2013 United States Santa Monica, United States 6 employees Grant Total: $17.40M Biotechnology, Health Care +1

General Information

Company Name Trethera
Founded Year 2013
Location United States Santa Monica, United States
Employees 6
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Trethera. To contact Trethera, visit trethera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Trethera

Trethera is a biotechnology startup based in Santa Monica, CA, and was founded in 2015. The company focuses on developing safer, more affordable, and efficacious treatments for oncology indications. Trethera capitalizes on novel insights into cancer metabolism during rapid DNA replication and aims to develop small molecule compounds to precisely target these pathways. The company's therapeutic approaches involve targeting multiple pathways using rationally-designed combinations of drugs, with the goal of improving efficacy and overcoming the limitations of previous single agent therapies. On 25 September 2023, Trethera received a $400.00K grant investment from the National Institute of Diabetes and Digestive and Kidney Diseases. This investment signifies a recognition of Trethera's potential to make a significant impact in the field of oncology treatment. With its innovative approach and strong investor backing, Trethera is well-positioned to make strides in the biotechnology and healthcare industries, potentially transforming the landscape of cancer treatment.

Taxonomy: oncology, cancer treatment, DNA replication, metabolic pathways, small molecule compounds, combination therapies, drug development, treatment efficacy, biopharmaceutical, precision medicine, Santa Monica, California, startup, investor analysis

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $400.00K 1
National Institute of Diabetes and Digestive and Kidney Diseases
25 Sep 2023
Grant $6.00M 1
National Institute of Allergy and Infectious Diseases
14 Aug 2023
Grant $2.00M 1
National Cancer Institute
30 May 2023
Grant $1.60M 1
National Eye Institute
19 Oct 2022
Venture Round $7.40M -
23 Feb 2016

Trethera Alternatives & Competitors

View All Alternatives
Trethera vs
Kintara Therapeutics, Inc. NASDAQ: KTRA
Kintara Therapeutics, Inc. NASDAQ: KTRA United States

Seeking New Horizons for Cancer Patients

Grant
8 employees
Biotechnology, Health Care
Trethera vs
Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. United States

Lixte Biotechnology (Nasdaq: LIXT)

Post-IPO Equity
6 employees
Biotechnology, Health Care
Trethera vs
Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. United States

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developin...

Post-IPO Equity
10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Trethera

Based in Santa Monica, CA, Trethera is a privately-held company that aims to develop safer, more affordable and efficacious treatments for indications in oncology. The company is capitalizing on novel insights into the metabolic demands and vulnerabilities of cancer during rapid DNA replication and...
Trethera was founded in 2013.
Trethera is headquartered in Santa Monica, United States.
Trethera operates in Biotechnology, Health Care and Medical Devices. Its work centres on oncology, cancer treatment, DNA replication and metabolic pathways.
Trethera has approximately 6 employees.
Trethera has completed 5 funding rounds, raising a total of $17.40M. The latest funding stage is Grant.
Top alternatives and competitors to Trethera include Kintara Therapeutics, Inc. NASDAQ: KTRA, Lixte Biotechnology Holdings, Inc., Cascadian Therapeutics, Inc., Apollomics, Anchiano Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trethera and Kintara Therapeutics, Inc. NASDAQ: KTRA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Trethera, https://bouncewatch.com/company/trethera, updated 29 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes